A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
phase-1 study pneumococcal conjugate vaccine study in healthy adults

Detailed Description
-----------------
A Study to Evaluate the Safety and Immunogeneicity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy adults

Official Title
-----------------
Single-blind, Single-center, Randomized, Active-controlled, Parallel Group, Phase I Study to Evaluate the Safety and Immunogenicity of Intramuscular Single Injection With Pneumococcal Conjugate Vaccine or Prevnar13 in Healthy Adults

Conditions
-----------------
Pneumococcal Infection

Intervention / Treatment
-----------------
* Biological: LBVE01
* Biological: LBVE02
* Biological: Prevnar13


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adult older than 19 years old and younger than 50 years old A subject who was informed of the purpose, method, and efficacy of the clinical study and signed the written informed consent form Exclusion Criteria: A subject who participated in other clinical studies within 3 months before screening A subject who was vaccinated with other vaccines within 4 weeks before screening, or who is expected to receive other vaccination during the clinical study period A subject with medical history of hypersensitive reactions (e.g. anaphylaxis) to the test drug or its ingredients A subject who received immunoglobulin or blood-derived materials within 3 months before screening A subject with immunologic function disorders including congenital or acquired immunodeficiency disorders A subject who is receiving immunosuppressive therapy or drugs that can affect immunological reaction A subject with pyrexia of over 38 Celsius degrees on the day of the vaccination with the investigational products A subject with medical history of Invasive Pneumococcal Disease (IPD) or pneumonia caused by Streptococcus pneumoniae A subject who was vaccinated with any pneumococcal vaccine before screening A subject who received the vaccine containing diphtheria toxoid within 6 months before screening (e.g. adult Td vaccine)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LBVE01<br>Multivalent pneumococcal conjugate vaccine | Biological: LBVE01<br>* Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh<br>|
| Experimental: LBVE02<br>Multivalent pneumococcal conjugate vaccine | Biological: LBVE02<br>* Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh<br>|
| Active Comparator: Prevnar13<br>Multivalent pneumococcal conjugate vaccine Prevnar13 | Biological: Prevnar13<br>* 13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Solicited adverse events | Solicited adverse events | Baseline(pre-vaccination) up to 7 days after | 
| Unsolicited adverse events | Unsolicited adverse events | Baseline(pre-vaccination) up to 4 weeks after vaccination | 
| Immediate reactions after vaccination | Immediate reactions after vaccination | Baseline(pre-vaccination) up to 30 minutes after vaccination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serotype-Specific Pneumococcal immunoglobulin G antibody Geometric Mean Concentrations (GMCs) 4 weeks After Vaccination | GMC | 4 weeks After Vaccination | 
| Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 4 weeks After Vaccination | GMT | 4 weeks After Vaccination | 
| Proportion of subjects achieving 4-fold rise in Pneumococcal Opsonophagocytic Activity (OPA) titer at 4 weeks after vaccination | OPA titer | 4 weeks after vaccination |